FDA Finds No Cancer Link for Ezetimibe or Simvastatin

A review of data from three studies indicates that neither simvastatin, ezetimibe, or the combination of the two are likely to increase the risk of cancer or death from cancer, but that the association cannot be “definitively ruled out,” the Food and Drug Administration said.